Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The HVTN protocol 903 vaccine preparedness study: Lessons learned in preparation for HIV vaccine efficacy trials
Journal of Acquired Immune Deficiency Syndromes, Volume 48, No. 1, Year 2008
Notification
URL copied to clipboard!
Description
Successful recruitment and retention of HIV-uninfected at-risk participants are essential for HIV vaccine efficacy trials. A multicountry vaccine preparedness study was started in 2003 to assess enrollment and retention of HIV-negative high-risk participants and to assess their willingness to participate in future vaccine efficacy trials. HIV-negative high-risk adults were recruited in the Caribbean, in Southern Africa, and in Latin America, and were followed for 1 year. Participants included men who have sex with men, heterosexual men and women, and female sex workers. History of sexually transmitted infections and sexual risk behaviors were recorded with HIV testing at 0, 6, and 12 months, and willingness to participate in future vaccine trials was recorded at 0 and 12 months. Recruitment, retention, and willingness to participate in future trials were excellent at 3 of the 6 sites, with consistent declines in risk behaviors across cohorts over time. Although not powered to measure seroincidence, HIV seroincidence rates per 100 person-years (95% confidence interval [CI]) were as follows: 2.3 (95% CI: 0.3 to 8.2) in Botswana, 0.5 (95% CI: 0 to 2.9) in the Dominican Republic, and 3.1 (95% CI: 1.1 to 6.8) in Peru. The HIV Vaccine Trials Network 903 study helped to develop clinical trial site capacity, with a focus on recruitment and retention of high-risk women in the Americas, and improved network and site expertise about large-scale HIV vaccine efficacy trials. © 2008 Lippincott Williams & Wilkins, Inc.
Authors & Co-Authors
Djomand, Gaston
United States, Seattle
Hiv Vaccine Trials Network
Metch, B.
United States, Seattle
Hiv Vaccine Trials Network
Zorrilla, Carmen D.
Puerto Rico, San Juan
Universidad de Puerto Rico
Donastorg, Yeycy
Dominican Republic, Santo Domingo
Instituto Dermatológico y Cirugía de Piel “dr. Huberto Bogaert Díaz”
Casapia, Martin
Peru, Iquitos
Asociación Civil Selva Amazónica
Villafana, Tonya L.
Botswana, Gaborone
Botswana Harvard Aids Institute Partnership
Pape, Jean William
Haiti, Port-au-prince
Groupe D’étude Haïtien Sur le Sarcome de Kaposi et Les Infections Opportunistes
Figueroa, John Peter
Jamaica, Kingston
Epidemiology Research and Training Unit
Hansen, Marianne
United States, Seattle
Hiv Vaccine Trials Network
Buchbinder, Susan P.
Unknown Affiliation
Beyrer, Chris C.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
United States, Baltimore
Johns Hopkins University
Statistics
Citations: 34
Authors: 11
Affiliations: 9
Identifiers
Doi:
10.1097/QAI.0b013e31817236ab
ISSN:
15254135
Research Areas
Infectious Diseases
Sexual And Reproductive Health
Study Design
Cohort Study
Study Locations
Botswana
Participants Gender
Male
Female